Monte Rosa Therapeutics, Inc. (GLUE) Stock Price & Analysis
Monte Rosa Therapeutics, Inc. (GLUE) fell 2.29% to USD 16.61 as of June 10, 2026 at 00:51 UTC, according to Nexqual real-time market data.
GLUE last closed at USD 17; the session ranged USD 16.15–17.83 on volume of 817,602 shares. Market capitalization is $1.40B, with a 52-week range of USD 4.12–25.77 (NMS). Source: Nexqual, June 10, 2026 at 00:51 UTC.
Key Statistics (as of June 10, 2026 at 00:51 UTC)
| Price | USD 16.61 |
|---|---|
| Change | ▼ 2.29% (down) |
| Previous Close | USD 17 |
| Open | USD 17.49 |
| Day Range | USD 16.15 – 17.83 |
| 52-Week Range | USD 4.12 – 25.77 |
| Volume | 817,602 shares |
| Market Cap | $1.40B |
| Exchange | NMS |
Technical Analysis (GLUE)
Nexqual's technical model rates GLUE "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:51 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 33.58 (neutral) |
| vs SMA50 | Below (USD 18.53) |
| MACD | -0.48 (negative) |
Analyst Ratings (GLUE)
Wall Street analysts rate GLUE "Strong Buy" based on 6 analysts, with a mean price target of USD 32.33 (range USD 29–37), per Nexqual as of June 10, 2026 at 00:51 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 32.33 |
| High Target | USD 37 |
| Low Target | USD 29 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (GLUE)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.37 |
| Revenue Estimate | $12.88M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.45 vs est -0.38 ▼ miss |
| 2025-12-31 | USD -0.55 vs est -0.34 ▼ miss |
| 2025-09-30 | USD -0.33 vs est -0.35 ▲ beat |
| 2025-06-30 | USD -0.15 vs est -0.36 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:51 UTC.
Financials & Fundamentals (GLUE)
| Total Revenue | $42.95M |
|---|---|
| Revenue Growth (YoY) | -95.00% |
| Gross Margin | -238.54% |
| Operating Margin | -1188.46% |
| Profit Margin | +0.00% |
| ROE | -32.62% |
| Debt / Equity | 7.49 |
| Current Ratio | 9.54 |
| Total Cash | $666.22M |
| Total Debt | $39.06M |
| Free Cash Flow | $-77.16M |
Source: Nexqual, June 10, 2026 at 00:51 UTC.
Financial Health Score (GLUE)
Nexqual rates Monte Rosa Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:51 UTC.
| Growth | Strong — Revenue +64% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $666M cash vs $39M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$77M, burning cash |
| Efficiency | Critical — ROE -33%, ROA -16.4% |
Ownership (GLUE)
| Insider Ownership | +0.58% |
|---|---|
| Institutional Ownership | +113.14% |
| Shares Outstanding | 84.48M |
| Float | 53.00M |
| Short % of Float | +17.99% |
Source: Nexqual, June 10, 2026 at 00:51 UTC.
Leadership (GLUE)
Monte Rosa Therapeutics, Inc. is led by Markus Warmuth (age 54), President, CEO & Director, per Nexqual as of June 10, 2026 at 00:51 UTC.
| President, CEO & Director | Markus Warmuth (age 54) |
|---|---|
| Chief Operating Officer | Jennifer Champoux (age 53) |
| Chief Technology Officer | Magnus Walter DPHIL |
| Chief Scientific Officer | Sharon Townson (age 50) |
Major Backers & Investors (GLUE)
Notable institutional backers of Monte Rosa Therapeutics, Inc. include NEA Management Company, LLC, Price (T.Rowe) Associates Inc, TCG Crossover Management, LLC, according to Nexqual as of June 10, 2026 at 00:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| NEA Management Company, LLC | 9.11% |
| Price (T.Rowe) Associates Inc | 9.02% |
| TCG Crossover Management, LLC | 5.47% |
| BVF Inc. | 5.28% |
| T. Rowe Price | 5.23% |
| Baker Bros. Advisors, LP | 5.14% |
| Suvretta Capital Management, LLC | 5% |
| Vestal Point Capital, LP | 4.27% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.97% |
| State Street | 6.54% |
Source: Nexqual, June 10, 2026 at 00:51 UTC.
From Monte Rosa Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
- The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.
- In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast.
- Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IPSC | Century Therapeutics, Inc. | USD 2.21 | ▲ 3.76% |
| EWTX | Edgewise Therapeutics, Inc. | USD 34.06 | ▼ 4.3% |
| ERAS | Erasca, Inc. | USD 13.41 | ▲ 12.03% |
| DSGN | Design Therapeutics, Inc. | USD 10.55 | ▼ 0.94% |
| CGEM | Cullinan Therapeutics, Inc. | USD 13.18 | ▼ 2.44% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:51 UTC. This page is informational and not investment advice.